NUVA

NuVasive, Inc. (NUVA) | Rumor.io

NuVasive

NUVA

Attention (50-day avg)0%

Attention rank (50-day avg)—

Bullish sentiment (50-day avg)100%

Price to earnings ratio0

Market capitalization0

Earnings per share0

Dividend yield (TTM)—

Revenue (annual)0

Net income (annual)0

Social

What share of all stock conversation is about NUVA?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% 0	0% 0	0% 0

May 10

NuVasive, Inc. ($NUVA) reports Q1 2023 earnings of 47c EPS and $307.71M revenue, beating Estimize Consensus by 3c EPS and $7.87M revenue.
The company guides FY23 revenue in-line and reports a 5% YoY increase in revenue per share for Q1.
NuVasive's Q1 2023 financial results include a GAAP EPS of -$0.02 and revenue of $307.71M, with the company filing Form 10-Q and Form 425 on May 10.

Generated by AI

Sentiment

Of the messages about NUVA that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	—	—	100% +6.57
Bearish	—	—	—	0% -6.57

Bullish· Dec 13

NuVasive's rating has been increased to Outperform by several brokerages, including Leerink Swann and SVB Leerink, with price targets ranging from $74 to $92.
Analysts expect NuVasive to announce earnings of $0.63 per share for the current quarter, indicating a potential positive impact on the company's stock price.
The stock has entered an uptrend, with a recent 2.44% change and a new 52-week high, suggesting a strong bullish momentum for NuVasive.

Bearish· Aug 28

NuVasive, Inc. ($NUVA) was downgraded to "Underperform" by Needham & Company LLC due to overvaluation.
The company's stock rating was lowered by Needham & Company LLC, citing concerns about the stock's price-to-earnings multiples.
A recent technical alert for $NUVA indicated a bearish signal line cross, suggesting a potential decline in the stock's price.

Generated by AI

Topics

Of the messages about NUVA that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Analysts	—	—	—	0%
Announcements	—	—	—	82.14%
Controversies	—	—	—	0%
Earnings	—	—	—	0%
Macro	—	—	—	0%
Technical Analysis	—	—	—	17.86%

Earnings· Jul 31

NuVasive's Q2 earnings of $0.58 EPS and $281.56M Revs beat Estimize Revenue Consensus by $5.27M.
The company lowered FY18 EPS guidance to $2.37-2.40, excluding non-recurring items, below consensus of $2.44.
NuVasive updated FY18 revenue guidance to $1.095-1.105 billion.

Analysts· Nov 10

Needham analyst David Saxon maintains NuVasive with a Buy and lowers the price target from $73 to $64.
Citigroup lowers NuVasive's price target to $70 from $82, with a Buy rating.
Canaccord Genuity cuts NuVasive's price target to $60, with a Hold rating.

Announcements· Feb 9

Globus Medical is acquiring NuVasive in an all-stock transaction valued at $3.1 billion, with NuVasive shareholders receiving $0.75 per share of Globus common stock.
The deal values NuVasive at $57.72 per share, with an equity value of $3.1 billion based on Globus Medical's closing share price on February 8.
NuVasive shareholders will exchange each share of NuVasive common stock for 0.75 of a share of Globus Medical Class A common stock at the closing of the transaction.

Generated by AI

Community

Of the messages about NUVA, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	—	100%	100%	81.18%
Newcomers	—	0%	0%	18.82%

Regulars· Apr 28

NuVasive, Inc. ($NUVA) receives new coverage from analysts, which may impact its stock price.
The stock has seen significant trading activity, with multiple large prints, indicating strong investor interest.
A comparison of NuVasive and Globus Medical ($GMED) suggests that Globus Medical may be a more profitable investment option.

Newcomers· Feb 9

NuVasive may see a higher bid given its valuation for the proposed acquisition by Globus Medical, according to an analyst.
The proposed acquisition of NuVasive by Globus Medical in an all-stock deal is valued at $3.1 billion, with NuVasive shareholders receiving 0.75 of a share of Globus Medical common stock for each share of NuVasive common stock.
The deal is expected to create an innovative global musculoskeletal company focused on patient care, combining the strengths of both Globus Medical and NuVasive.

Generated by AI

Also Discussed

Investors talking about NUVA also mention

#	Name	Attention
1	Zimmer Biomet Holdings, Inc.ZBH	0%0
2	Globus Medical Inc. Class A Common StockGMED	0%new
3	AMED - Amedisys, Inc.	——
4	AtriCure Inc.ATRC	0%0
5	CONMED CorporationCNMD	0%new
6	Stryker CorporationSYK	0.01%+0.01
7	CSII - Cardiovascular Systems, Inc.	——
8	Orthofix Medical Inc.OFIX	0%0
9	Merit Medical Systems, Inc.MMSI	0%0
10	Edwards Lifesciences CorporationEW	0%new

NuVasive, Inc.

Location

Social

What share of all stock conversation is about NUVA?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% 0	0% 0	0% 0

May 10

NuVasive, Inc. ($NUVA) reports Q1 2023 earnings of 47c EPS and $307.71M revenue, beating Estimize Consensus by 3c EPS and $7.87M revenue.
The company guides FY23 revenue in-line and reports a 5% YoY increase in revenue per share for Q1.
NuVasive's Q1 2023 financial results include a GAAP EPS of -$0.02 and revenue of $307.71M, with the company filing Form 10-Q and Form 425 on May 10.

Generated by AI

Sentiment

Of the messages about NUVA that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	—	—	100% +6.57
Bearish	—	—	—	0% -6.57

Bullish· Dec 13

NuVasive's rating has been increased to Outperform by several brokerages, including Leerink Swann and SVB Leerink, with price targets ranging from $74 to $92.
Analysts expect NuVasive to announce earnings of $0.63 per share for the current quarter, indicating a potential positive impact on the company's stock price.
The stock has entered an uptrend, with a recent 2.44% change and a new 52-week high, suggesting a strong bullish momentum for NuVasive.

Bearish· Aug 28

NuVasive, Inc. ($NUVA) was downgraded to "Underperform" by Needham & Company LLC due to overvaluation.
The company's stock rating was lowered by Needham & Company LLC, citing concerns about the stock's price-to-earnings multiples.
A recent technical alert for $NUVA indicated a bearish signal line cross, suggesting a potential decline in the stock's price.

Generated by AI

Topics

Of the messages about NUVA that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Analysts	—	—	—	0%
Announcements	—	—	—	82.14%
Controversies	—	—	—	0%
Earnings	—	—	—	0%
Macro	—	—	—	0%
Technical Analysis	—	—	—	17.86%

Earnings· Jul 31

NuVasive's Q2 earnings of $0.58 EPS and $281.56M Revs beat Estimize Revenue Consensus by $5.27M.
The company lowered FY18 EPS guidance to $2.37-2.40, excluding non-recurring items, below consensus of $2.44.
NuVasive updated FY18 revenue guidance to $1.095-1.105 billion.

Analysts· Nov 10

Needham analyst David Saxon maintains NuVasive with a Buy and lowers the price target from $73 to $64.
Citigroup lowers NuVasive's price target to $70 from $82, with a Buy rating.
Canaccord Genuity cuts NuVasive's price target to $60, with a Hold rating.

Announcements· Feb 9

Globus Medical is acquiring NuVasive in an all-stock transaction valued at $3.1 billion, with NuVasive shareholders receiving $0.75 per share of Globus common stock.
The deal values NuVasive at $57.72 per share, with an equity value of $3.1 billion based on Globus Medical's closing share price on February 8.
NuVasive shareholders will exchange each share of NuVasive common stock for 0.75 of a share of Globus Medical Class A common stock at the closing of the transaction.

Generated by AI

Community

Of the messages about NUVA, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	—	100%	100%	81.18%
Newcomers	—	0%	0%	18.82%

Regulars· Apr 28

NuVasive, Inc. ($NUVA) receives new coverage from analysts, which may impact its stock price.
The stock has seen significant trading activity, with multiple large prints, indicating strong investor interest.
A comparison of NuVasive and Globus Medical ($GMED) suggests that Globus Medical may be a more profitable investment option.

Newcomers· Feb 9

NuVasive may see a higher bid given its valuation for the proposed acquisition by Globus Medical, according to an analyst.
The proposed acquisition of NuVasive by Globus Medical in an all-stock deal is valued at $3.1 billion, with NuVasive shareholders receiving 0.75 of a share of Globus Medical common stock for each share of NuVasive common stock.
The deal is expected to create an innovative global musculoskeletal company focused on patient care, combining the strengths of both Globus Medical and NuVasive.

Generated by AI

NuVasive

Social

May 10

Sentiment

Bullish· Dec 13

Bearish· Aug 28

Topics

Earnings· Jul 31

Analysts· Nov 10

Announcements· Feb 9

Community

Regulars· Apr 28

Newcomers· Feb 9

Also Discussed

NuVasive, Inc.

Company Information

Location

Also Discussed

Social

May 10

Sentiment

Bullish· Dec 13

Bearish· Aug 28

Topics

Earnings· Jul 31

Analysts· Nov 10

Announcements· Feb 9

Community

Regulars· Apr 28

Newcomers· Feb 9